ConductScience.org, home

Comparison · NCT03358576-deaths

Sulopenem vs Ertapenem: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Sulopenem vs Ertapenem: deaths from any cause. Trial comparisons, record NCT03358576-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03358576-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01180.004610.03wilson
Risk in group 20.01190.004640.0302wilson
Risk difference, group 1 minus group 2-0.0000704-0.01970.0195newcombe hybrid score
Risk ratio, group 1 over group 20.9940.2513.94log
Odds ratio, group 1 over group 20.9940.2474.01log
Number needed to treat, for one fewer death from any cause on Sulopenem than on Ertapenem14,200from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Sulopenem
Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment~Sulopenem-Etzadroxil/Probenecid: Antibiotic for complicated intra-abdominal infection~Sulopenem: Antibiotic for complicated intra-abdominal infection
4338EG000
Group 2Ertapenem
Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead~Ertapenem: Antibiotic for complicated intra-abdominal infection~Ciprofloxacin: Antibiotic for complicated intra-abdominal infection~Metronidazole: Antibiotic for complicated intra-abdominal infection~Amoxicillin-Clavulanate: Antibiotic for complicated intra-abdominal infection
4336EG001

Harm

What it counts
Total, all-cause mortality
Time frame
From the time of informed consent through the test-of-cure visit, an average of 28 days

Source ClinicalTrials.gov

Trial

Title
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
NCT number
NCT03358576
Phases
PHASE3
Conditions
Intra Abdominal Infections
Interventions
Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, Metronidazole, Amoxicillin-Clavulanate, Sulopenem
Lead sponsor
Iterum Therapeutics, International Limited
Results first posted
2020-12-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03358576-deaths